Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 10, 2011 Brian Orelli	By the Way, We Need to Run Another Trial InterMune has decided to run a new trial to gain U.S. approval on its idiopathic pulmonary fibrosis drug.
The Motley Fool March 10, 2010 Brian Orelli	Up 160% With Room to Run You've got to love biotech and InterMune.
The Motley Fool December 7, 2006 Brian Lawler	The Best Small Cap for 2007: Encysive Pharmaceuticals This little drug maker has the potential for big profit, in both the U.S. and Europe. Investors, take note.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool February 3, 2009 Brian Orelli	InterMune Batting .500 The results weren't exactly what Rule Breakers pick InterMune was looking for, but things could have been worse -- and the stock is up 38% today on the news.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool April 30, 2004 Charly Travers	Sales Weakness From InterMune Biotechnology company InterMune would seem to be in good shape with a drug, Actimmune (which helps boost the immune system of cancer patients and others). The drug, however, has been showing quarterly sales weakness since early 2003, a trend that now seems like it may continue into the future.
The Motley Fool March 4, 2011 Brian Orelli	Up 15% for That? InterMune investors react to a non-event.
The Motley Fool March 6, 2007 Brian Lawler	InterMune Swoons Shares of InterMune fall after it announces negative clinical trial results for one of its drugs.
The Motley Fool December 19, 2008 Brian Orelli	Eli Lilly's Good News Misses the Mark EU approval of its blood thinner is nice, but U.S. approval is what will really matter.
The Motley Fool March 7, 2007 Brian Lawler	Encysive's Outback Adventures The pharmaceutical gains marketing approval for its lead compound in Australia. Investors, take note.
The Motley Fool June 29, 2009 Brian Orelli	Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug.
The Motley Fool June 18, 2007 Brian Lawler	Gilead Gets the Payoff Gilead gets marketing approval for one of its drug candidates. Investors, take note.
The Motley Fool January 28, 2008 Brian Lawler	Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin?
The Motley Fool May 3, 2010 Brian Orelli	While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind.
The Motley Fool May 30, 2008 Brian Lawler	Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products.
The Motley Fool June 2, 2006 Brian Lawler	Encysive Can Breathe Easier The pharmaceutical's crucial Thelin drug gains EU approval. Encysive's next critical hurdle lies here in the U.S. Whatever the FDA's decision, expect more volatility in Encysive shares.
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
The Motley Fool December 26, 2006 Brian Lawler	InterMune's Secret Drug Surprise Shares of InterMune have risen after positive trial results for one of its top drug candidates. Investors, take note.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool October 7, 2010 Brian Orelli	Asset Sold, Questions Begin Why did InterMune sells its stake in danoprevir?
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool August 4, 2005 Charly Travers	This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note.
The Motley Fool April 15, 2011 Brian Orelli	Fewer Needle Pricks for the Europeans Amylin's once-weekly diabetes drug Bydureon gets a positive recommendation in Europe.
The Motley Fool August 7, 2007 Brian Lawler	Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential.
The Motley Fool December 20, 2010 Brian Orelli	A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto.
The Motley Fool March 21, 2007 Brian Lawler	InterMune Slims Down InterMune announces changes after its lead compound fails in a study. Investors, take note.
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool May 28, 2009 Robert Steyer	Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena.
Chemistry World August 29, 2014 Sarah Houlton	Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion.
The Motley Fool September 25, 2007 Brian Orelli	Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool June 26, 2009 Brian Orelli	Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market.
The Motley Fool May 13, 2011 Brian Orelli	FDA Advisory Panel Positive! Shares Punished. Despite the positive recommendation, investors aren't convinced BioMimetic's Augment will be approved.
The Motley Fool April 29, 2008 Brian Orelli	Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool February 22, 2008 Brian Lawler	The Hypertension Fight Expands News from the pharmaceutical industry regarding hypertension medications: Gilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
The Motley Fool February 18, 2005 Charly Travers	A Drug to Get Your Blood Pumping Encysive's Thelin combines low risk with high sales potential.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool March 20, 2009 Brian Orelli	EU to Gilead: More Trials for You The U.S. isn't ready for Gilead Sciences' new cystic fibrosis drug, and neither is Europe.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool May 11, 2006 Brian Lawler	Encysive Evasive About Thelin The pharmaceutical stays tight-lipped about FDA approval of its new drug. Investors should keep an eye on Encysive's cash-burn rate in the coming months.
The Motley Fool June 15, 2007 Brian Lawler	Encysive's Date With Destiny Approaches A decision on the specialty drugmaker's lead drug is imminent. Betting against the FDA is generally not a good idea for investors. Here are statements from Encysive's past press releases about Thelin
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool June 18, 2007 Brian Lawler	The Third Time Isn't the Charm for Encysive The approvable letter for the pulmonary arterial hypertension treatment marks the third time Thelin has failed to get full approval from the FDA. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool April 3, 2009 Brian Orelli	Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool August 2, 2007 Brian Lawler	United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note.